A Multicenter Randomized Phase III Study of Pemetrexed Versus Erlotinib in Patients With Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Trial Profile

A Multicenter Randomized Phase III Study of Pemetrexed Versus Erlotinib in Patients With Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2013

At a glance

  • Drugs Pemetrexed (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 09 May 2013 Primary endpoint 'Time-to-disease-progression' has not been met.
    • 18 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Jun 2010 Results presented at the 46th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top